On September 20, 2021, Charles M. Baum, M.D., Ph.D., transitioned from President and Chief Executive Officer and principal executive officer of Mirati Therapeutics, Inc. (the Company) to President, Founder and Head of Research and Development of the Company. Dr. Baum will continue to lead the Company's research and development efforts and serve as a member of the Company's Board of Directors (the Board"). On September 20, 2021, David Meek was appointed as the Company's Chief Executive Officer and principal executive officer, and Charles M. Baum, M.D., Ph.D., was appointed as the Company's President, Founder and Head of Research and Development. Mr. Meek, age 58, previously served as the President, Chief Executive Officer and Board Member of FerGene, Inc. from January 2020 to March 2021. From July 2016 to January 2020, Mr. Meek served as Chief Executive Officer of Ipsen, a public global biopharmaceutical company based in France. Prior to joining Ipsen, Mr. Meek held numerous leadership roles including serving as Executive Vice President of Oncology at Baxalta Incorporated from 2014 to 2016, serving as Chief Commercial Officer of Endocyte, Inc. from 2012 to 2014.